ADAM10 and colorectal carcinoma: Finally, treatment studies in CRC cell line-derived xenograft models revealed marked antitumorigenic properties of 1H5.<h4>Discussion</h4>Together, these findings demonstrate that selective targeting of the active conformation of ADAM10 enables simultaneous inhibition of multiple oncogenic pathways involved in CRC growth and progression and represents a promising therapeutic strategy warranting further clinical evaluation.